# Martin Münchbach

> Martin Münchbach is a Series A investor at Pureos Bioventures backing Biotechnology and Medical. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pureos Bioventures](https://shizune.co/investors/profile/pureos-bioventures)
- Total investments: 12
- Last investment: Apr 2023
- Lead investor: 8%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/martin-m%C3%BCnchbach-1b88b1

Martin Münchbach is a Series A investor at Pureos Bioventures focused on Biotechnology and Medical. Martin is a founding partner of Pureos and has been a venture capital investor since 1999, investing in life science companies across all stages and types. Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management. Martin’s most successful investments and board assignments include Radius Health, MolecularPartners, Optimer, Axovan and Glycart. Martin is currently a BoD member at Ypsomed Holding, Alentis Therapeutics, binX Health, River Renal and SatoSea Oncology. Martin obtained his PhD in protein chemistry from the ETH Zurich and his MAS in Management, Technology, and Economics from ETH Zurich.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 33% |
| Medical | 3 | 25% |
| Pharmaceutical | 3 | 25% |
| Health Care | 2 | 17% |
| Therapeutics | 2 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 25% |
| Series B | 2 | 17% |
| Series C | 2 | 17% |
| Funding Round | 1 | 8% |
| Private Equity | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 25% |
| Germany | 1 | 8% |
| Switzerland | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ariceum Therapeutics | Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. | $25M | Series A | Apr 18, 2023 |  |
| Ariceum Therapeutics | Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. | $26.8M | Series A | Jun 08, 2022 |  |
| Radius Health | Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors. | $43M | Private Equity | Apr 25, 2013 |  |
| Radius Health | Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors. | $21.4M | Private Equity | Dec 16, 2011 |  |
| Radius Health | Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors. | $66M | Series C | Jul 26, 2011 |  |
| Tioga Pharmaceuticals | Tioga Pharmaceuticals, Inc. develops therapies for the treatment of gastrointestinal diseases. Its product includes asimadoline, an orally administered small molecule therapeutic for the treatment of irritable bowel syndrome and functional dyspepsia. The company was founded in 2005 and is based in San Diego, California. | $18M |  | Feb 17, 2010 |  |
| Molecular Partners | Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics. | $44.2M | Series B | Dec 16, 2009 |  |
| Radius Health | Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors. | $15M | Series C | Nov 20, 2008 |  |
| BioVascular | BioVascular is a clinical stage privately held biotechnology company developing “first in class” products for platelet mediated cardiovascular diseases.BioVascular’s initial product, saratin, is a polypeptide produced by recombinant means in yeast. This product was discovered by and licensed from Merck KGaA. BioVascular is conductinghuman clinical trials of saratin for use in hemodialysis access graft and peripheral artery grafts to reduce intimal hyperplasia, which can lead to failure of the graft. | $10.9M | Series C | Feb 07, 2008 |  |
| Molecular Partners | Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics. | $15.6M | Series A | Aug 14, 2007 |  |

10 of 12 investments shown.

## Co-investors
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 5 deals together
- [HealthCare Ventures](https://shizune.co/investors/profile/healthcare-ventures) — VC Fund, 4 deals together
- [Wellcome Trust](https://shizune.co/investors/profile/wellcome-trust) — VC Fund, 4 deals together
- [Brookside Capital](https://shizune.co/investors/profile/brookside-capital) — VC Fund, 3 deals together
- [Endeavour Vision](https://shizune.co/investors/profile/endeavour-vision) — VC Fund, 2 deals together
- [Forward Ventures](https://shizune.co/investors/profile/forward-ventures) — VC Fund, 2 deals together

## About Pureos Bioventures

VC Fund · Küsnacht, Switzerland

Pureos Bioventures is a new venture capital fund located in Zurich to exclusively invest in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats

4 contacts available at Pureos Bioventures.

| Name | Title | Profile |
| --- | --- | --- |
| Klaus Breiner | Managing Partner & Founding partner | https://shizune.co/investors/profile/klaus-breiner |
| Martin Münchbach | Managing Partner & Founding Partner | https://shizune.co/investors/profile/martin-mnchbach |
| Dominik Escher | Managing Partner & Founding partner | https://shizune.co/investors/profile/dominik-escher |
| Ximing Ding | Investment Manager | https://shizune.co/investors/profile/ximing-ding-d13b |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Martin Münchbach invest in?

Martin Münchbach invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Martin Münchbach last invest?

The most recent investment recorded for Martin Münchbach closed in Apr 2023. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co